The stock market experienced quite a bit of volatility during President Donald Trump's first 100 days in office.

It has seen a steady rise from $1.28 billion in 2024 to $1.36 billion in 2025, indicating a compound annual growth rate CAGR of 6.6%. The marked growth during the historic period can be attributed to ...

Market is Segmented by Type (Distributed BDU, Centralized BDU), by Application (BEV, PHEV). The Battery Disconnect Unit (BDU) Market was valued at USD 3657 Million in the year 2024 and is projected to ...

Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, has announced today the formation of its Scientific Advisory Board (SAB) comprised of biopharma industry ...

Artificial intelligence is gaining ground in healthcare, and tech's biggest players are racing to stake their claims.

Eli Lilly signs a global licensing deal with Rznomics to co-develop RNA-editing therapies for hearing loss, with potential ...

We recently published a list of 12 Best Major Stocks to Buy According to Billionaires. In this article, we are going to take ...

It has been corrected. A study of two blockbuster weight-loss drugs showed that users of Eli Lilly’s Zepbound lost just over 2 inches more off their waists compared with Novo Nordisk’s rival ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

Shares of Eli Lilly & Co. LLY advanced 2.48% to $733.29 Thursday, on what proved to be an all-around great trading session ...

Carrie Mckim; Investor Relations; Codexis Inc. Stephen Dilly; Chairman of the Board, President, Chief Executive Officer, Director; Codexis Inc. Stefan Lutz; Senior V ...

Eli Lilly has made a foray into the radiopharmaceuticals category with an agreement to buy POINT Biopharma for around $1.4 billion. If the $12.50-per-share all-cash deal is completed, it will give ...